Recent advances in rapid antimicrobial susceptibility testing systems. (3rd June 2021)

• Record Type: Journal Article
• Authors: Jacobs, Michael R.; Colson, Jordan D.; Rhoads, Daniel D.
• Is Part Of: Expert review of molecular diagnostics. Volume 21:Number 6(2021)
• Page Start: 563
• Page End: 578
• Publication Date: 2021-06-03
• Subjects: Antimicrobial susceptibility testing -- β-lactamase -- bloodstream infections -- genotype -- lateral flow assay -- maldi-tof ms -- MIC -- pcr -- phenotype -- whole-genome sequencing; Molecular diagnosis -- Periodicals; 616.0758205
• DOI: 10.1080/14737159.2021.1924679
• Languages: English
• ISSNs: 1473-7159

Abstract

ABSTRACT: Introduction: Until recently antimicrobial susceptibility testing (AST) methods based on the demonstration of phenotypic susceptibility in 16–24 h remained largely unchanged. Areas covered: Advances in rapid phenotypic and molecular-based AST systems. Expert opinion: AST has changed over the past decade, with many rapid phenotypic and molecular methods developed to demonstrate phenotypic or genotypic resistance, or biochemical markers of resistance such as β-lactamases associated with carbapenem resistance. Most methods still require isolation of bacteria from specimens before both legacy and newer methods can be used. Bacterial identification by MALDI-TOF mass spectroscopy is now widely used and is often key to the interpretation of rapid AST results. Several PCR arrays are available to detect the most frequent pathogens associated with bloodstream infections and their major antimicrobial resistance genes. Many advances in whole-genome sequencing of bacteria and fungi isolated by culture as well as directly from clinical specimens have been made but are not yet widely available. High cost and limited throughput are the major obstacles to uptake of rapid methods, but targeted use, continued development and decreasing costs are expected to result in more extensive use of these increasingly useful methods.